Our sales manager, Barry Feigelman and project manager Leslie Nemeth attended SOT and ARVO in Arizona and Orlando. Both meetings were were well attended and strong scientifically and should lead to some interesting collaborations. It looks like our industry is slowly recovering from the Great Recession and that the CRO industry is key in supporting preclinical drug development.

One area that we at CBI are developing an interest in is microimaging-which would include:

• SPECT
• PET
• CT
• Micro CT (in vivo and ex vivo, specimen)
• MRI
• Micro Ultrasound
• Optical
• Intravital Microscopy
• Microdialysis

To this end, we are working to collaborate with Biolaurus, a microimaging group with excellent expertise in this technology. Currently, we are planning for imaging in several models including Parkinson’s, Glomerular nephritis, bleomycin-induced pulmonary fibrosis and xenograft. Also, imaging can be conducted to assess nephrotoxicity of novel therapeutics as a form of safety pharmacology.